Methods are provided for the treatment of cardiovascular or metabolic diseasescharacterized by elevated serum total cholesterol, elevated serum LDL-cholesterol, or elevated serum triglycerides, through the administration of anoligomeric compound which modulates the levels or activity of miR-122a.Further provided are methods for reducing hepatic steatosis or liver tissuetriglyceride accumulation through the administration of an oligomeric compoundwhich modulates the levels or activity of miR-122a. Such methods employoligomeric compounds which hybridize with or sterically interfere with nucleicacid molecules comprising or encoding miR-122a. Such oligomeric compounds mayinclude one or more modifications thereon, which may improve the activity,stability, or nuclease resistance of the oligomeric compound. These modifiedoligomeric compounds are used as single compounds or in compositions,including pharmaceutical compositions, to modulate or mimic the targetednucleic acid comprising or encoding miR-122a.
